Historic HIV Vaccine Trial Involving GeoVax Vaccine Spotlighted in The Georgia Voice and The Body
Articles Highlight AIDS Research Consortium of Atlanta's Search for Volunteers To Help Test Safety of GeoVax's Vaccine in 77-Week Trial
SMYRNA, Ga., July 2 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc.
(OTC Bulletin Board: GOVX), a biotechnology company that creates,
develops and tests innovative HIV/AIDS vaccines, is mentioned in
two recent articles covering a historic HIV vaccine trial currently
being conducted by the AIDS Research Consortium of Atlanta (ARCA)
using a vaccine supplied by GeoVax.
The first article, titled "ARCA Seeks Volunteers For Historic
HIV Vaccine Trial," appeared in the June 11 print and online
editions of The Georgia Voice, a publication focused on Georgia's
LGBT community. In the article, Voice reporter Matt Shafer notes
that ARCA is currently seeking volunteers to help test the safety
of the GeoVax vaccine, which has shown the potential of reversing
HIV viral loads in HIV-positive individuals. He goes on to describe
how the vaccine works and details the stringent requirements for
participation. The article quotes ARCA's observation that this is
the first therapeutic trial ever conducted using a promising HIV
vaccine candidate from GeoVax.
The second article, titled "Georgia: AIDS Research Consortium of
Atlanta Seeks Volunteers for Historic HIV Vaccine Trial," was
posted on June 28 on the website The Body: The Complete HIV/AIDS
Resource. It is an excerpt of the Voice piece, once again reviewing
ARCA's search for trial subjects and stringent participation
requirements.
GeoVax CEO Dr. Robert McNally commented, "As I pointed out to
The Georgia Voice, we are hopeful that this vaccine will reproduce
its effects in humans the way it did in tests conducted on
primates. We anticipate that media coverage such as these articles
will make it easier to recruit appropriate test subjects, allowing
us to initiate the trial in a timely fashion and accelerate our
quest to bring a viable vaccine to market."
To read The Georgia Voice's article in its entirety, please
visit:
http://thegavoice.com/index.php/news/georgia-news-menu/507-arca-seeks-volu
nteers-for-historic-hiv-vaccine-trial
To read The Body's article in its entirety, please visit: http://www.thebody.com/content/art57219.html About GeoVax Labs, Inc.
GeoVax is a biotechnology company developing human vaccines for
diseases caused by HIV (Human Immunodeficiency Virus - that leads
to AIDS) and other infectious agents. Our goals include developing
HIV/AIDS vaccines for global markets, manufacturing and testing
these vaccines under GMP/GLP conditions (FDA guidelines),
conducting clinical trials for vaccine safety and effectiveness,
and obtaining regulatory approvals to move the product forward. All
preventative Phase 1 human clinical trials conducted to date tested
various combinations and doses of our DNA and MVA vaccines have
demonstrated the ability to raise anti-HIV immune responses as well
as for their safety. Successful results from all Phase 1 testing
supported the initiation of the first Phase 2 testing. GeoVax's
Phase 2 human trial began in January 2009 and will involve 225
participants at sites in the United States and South America.
Recently the FDA granted permission to proceed with a Phase 1
therapeutic trial for individuals infected with HIV. Long term, we
expect that GeoVax will grant manufacturing and distribution rights
in several global markets in return for upfront fees, collaborative
development agreements, and royalties on sales and distribution
revenues. Internal vaccine manufacturing and distribution will also
be considered by GeoVax. For more information, please visit
www.geovax.com.
Forward-Looking Statements
Certain statements in this document are "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act These statements are based on management's current
expectations and are subject to uncertainty and changes in
circumstances. Actual results may differ materially from those
included in these statements due to a variety of factors, including
whether: GeoVax can develop and manufacture these vaccines with the
desired characteristics in a timely manner, GeoVax's vaccines will
be safe for human use, GeoVax's vaccines will effectively prevent
AIDS in humans, vaccines will receive regulatory approvals
necessary to be licensed and marketed, GeoVax raises required
capital to complete
vaccine development, there is development of competitive
products that may be more effective or easier to use than GeoVax's
products, GeoVax will be able to enter into favorable manufacturing
and distribution agreements, and other factors, over which GeoVax
has no control. GeoVax assumes no obligation to update these
forward-looking statements, and does not intend to do so. More
information about these factors is contained in GeoVax's filings
with the Securities and Exchange Commission including those set
forth at "Risk Factors" in GeoVax's Form 10-K.
Contact At The Investor Relations Group: Investor Relations James Carbonara or Public Relations Janet Vasquez / Robin O'Malley (212) 825-3210
Source: GeoVax Labs, Inc.
CONTACT: At The Investor Relations Group: Investor Relations:
James
Carbonara, or Public Relations: Janet Vasquez or Robin
O'Malley,
+1-212-825-3210
Web Site: http://www.geovax.com/
Posted: July 2010
